Mitotech Ltd, a UK-based clinical-stage biotechnology company, is proud to announce that its CEO, Natalia Perekhvatova, is invited to present at OIS Dry Eye Innovation Showcase 2021. The event will take place on Mar 11, 2021. Hope to see you at OIS.
“We look forward to our presentation at the Dry Eye Innovation Showcase 2021 and to the opportunity to present our recent clinical results in Dry Eye – an exciting moment for us,” said Natalia Perekhvatova.
About Mitotech Ltd
Mitotech Ltd is a UK-based biotechnology company developing novel drugs for treatment of predominantly age-related disorders. The core technology behind Mitotech products is based on a novel class of small molecules – mitochondria targeting cardiolipin peroxidation inhibitors. Company's lead compound SkQ1 is being developed in several drug formulations covering a variety of therapeutic areas with major focus on ophthalmology and neurodegenerative diseases. In VISTA-1 – a Phase 2b/3 clinical study in the United States (NCT03764735) - SkQ1 showed evidence of efficacy in reducing both the signs and symptoms in Dry Eye subjects. Topline data from Mitotech's Phase 3 pivotal study (VISTA-2) is expected to be presented at Dry Eye Innovation Showcase 2021 on Mar 11. Dry AMD and LHON programs for SkQ1 ophthalmic solution are at pre-Phase 2 stage with Phase 2 studies projected to start in 2021.